IBanga le-877399-52-5 ye-Crizotinib ye-Anti-Cancer Treatment
Imvelisoigama | Crizotinib |
Izithethantonye | PF-02341066;3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl) ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine;PF 2341066 |
Inombolo yeCAS. | 877399-52-5 |
Imbonakalo | Umgubo wekristale omhlophe ukuya kumhlophe |
Ifomula yeemolekyuli | C21H22Cl2FN5O |
Ubunzima beMolekyuli | 450.34 |
Ukusetyenziswa | IBanga lezamayeza okanye injongo yoPhando |
Ukupakisha | Ngokwesicelo sakho |
Ugcino | Londoloza kwizikhongozeli eziqinile, ezikwaziyo ukumelana nokukhanya kwindawo epholileyo |
CrizotinibCas: 877399-52-5 | ||
Izinto | Iinkcukacha | Iziphumo |
Imbonakalo | Umgubo wekristale omhlophe ukuya kumhlophe | Umgubo omhlophe wekristale |
Ukuchongwa | H-NMR, MS | Iyahambelana |
Izinyibilikisi ezishiyekileyo | isopropanol≤0.5% EtOAc≤0.5% THF≤0.072% n-Heptane≤0.5% Toluene≤0.5% | 0.3% ND ND ND ND ND |
Iintsimbi ezinzima | ≤10ppm | Iyahambelana |
Isiqulatho samanzi | I-£0.5% | 0.3% |
Intsalela ekutshisweni | I-£0.5% | 0.05% |
I-Enantiomer | I-£0.1% | <LOQ |
Ukungcola okuNxulumeneyo yi-HPLC | Ukungcola okukodwa≤0.1% Ukungcola ngokupheleleyo ≤1.0% | 0.05% 0.12% |
Ubunyulu (HPLC) | ³99.0% | 99.88% |
Ulwazi lweNkampani
√ Amava apheleleyo omaleko wolawulo kumzi-mveliso kunye namagcisa anezakhono abalandeli; √ Umgangatho usoloko uyingqwalasela yethu ephezulu, inkqubo yeQC eQinisekileyo; √ Iminyaka eli-11 yamava eqela lokuthengisa kumazwe angaphandle; √ ilebhu yeR&D eZimeleyo; √ Iindibano zocweyo zeGMP ezimbini ezityikityiweyo zexesha elide; √ Imithombo etyebileyo yeefektri ezininzi ezingasebenziyo ukulungiselela iprojekthi elungelelanisiweyo; √ Iqela elisebenzayo eliSebenzayo ngokuSebenzayo ngendlela engaguqukiyo.Bhala umyalezo wakho apha kwaye uwuthumele kuthi